Language

Google Translate Disclaimer

A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

FIRST PARTICIPANT LEAVING FOR GROUND-BREAKING MS CLINICAL TRIAL

Released on August 16, 2012

A Key Step in the Province's Commitment to Advancing MS Research is Taking Place on Monday

The first Saskatchewan resident will fly to Albany, New York on Monday morning for the final stage of eligibility screening for a clinical trial of the effectiveness of Chronic Cerebro-Spinal Venous Insufficiency (CCSVI) in relieving symptoms of multiple sclerosis (MS).

The provincial government committed $2.2 million to have Saskatchewan patients participate in the Albany clinical trial to further research in this area and allow Saskatchewan residents to play an active role in MS research.

Andrew Dahlen of Saskatoon will travel to Albany to find out if he can participate in a two-year clinical study of the Liberation Therapy method of treating symptoms of the neurological disease.

"This is a ground-breaking day for our province and for science," Health Minister Dustin Duncan said. "I wish Andrew a safe journey and thank him for his willingness to help advance our knowledge about the value of CCSVI as a treatment for MS."

All prospective Saskatchewan participants in the clinical trial must first be screened by a Saskatchewan neurologist to ensure they meet eligibility requirements. They would then spend several days at Albany Medical Centre, where a final assessment will determine whether they will be accepted into the trial.

Half of the research participants will have angioplasty to ease congestion in the veins, and the other half will not. This double-blind approach is a standard scientific method to ensure the integrity of the research results.

The Saskatchewan neurologist will assist the Albany research team with assessments, referrals and ongoing monitoring of Saskatchewan participants.

"I'm excited to be one of the volunteers involved, and to contribute to this research process," Dahlen said. "I believe this research will provide information that will help MS patients in the future."

An estimated 3,500 Saskatchewan residents have MS, which impairs or destroys the functioning of nerve cells in the brain and spinal cord. The MS prevalence in Canada and especially the prairies is among the highest in the world.

-30-

For more information, contact:

Tyler McMurchy
Health
Regina
Phone: 306-787-4083

We need your feedback to improve saskatchewan.ca. Help us improve